CHAL 2 |
| Drug discovery process has been markedly facilitated by advances in genome sequencing, identification of genes associated with diseases, and state-of-the-art techniques of high throughput screening assay. Target validation and lead identification steps are critical for the discovery process, which routinely utilize gene/protein sequence data. Due to dramatic increases in the number of sequence claimed as intellectual properties, target validation processes should be followed by the clearance of freedom-to-operate (FTO) issues in using sequence of potential drug targets in order to avoid infringing patents claiming sequences of interest. This presentation discusses some of the challenges, search scopes/criteria of the sequence searches, and suggests ways to alleviate difficulties in conducting sequence-based patent information searches associated with freedom-to-operate issues. |
|
The Many Faces of CHAL: Where Chemistry Meets the Law
9:00 AM-11:30 AM, Sunday, 26 March 2006 Georgia World Congress Center -- C210, Oral
Division of Chemistry and the Law |